FTRE Key Statistics, Chart & Performance
The current stock price of FTRE is 11.59 USD. In the past month the price decreased by -33.28%. In the past year, price decreased by -22.58%.
FTRE Technical Analysis
FTRE Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to FTRE. FTRE has a bad profitability rating. Also its financial health evaluation is rather negative.
FTRE Financial Highlights
Over the last trailing twelve months FTRE reported a non-GAAP Earnings per Share(EPS) of 0.51. The EPS increased by 45.71% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -37.01% | ||
| ROE | -174.74% | ||
| Debt/Equity | 1.81 |
FTRE Forecast & Estimates
16 analysts have analysed FTRE and the average price target is 17.14 USD. This implies a price increase of 47.85% is expected in the next year compared to the current price of 11.59.
For the next year, analysts expect an EPS growth of 62.32% and a revenue growth 0.91% for FTRE
FTRE Ownership
FTRE Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 21.24 | 202.808B | ||
| DHR | DANAHER CORP | 25.9 | 155.22B | ||
| BRKRP | BRUKER CORP - BRKR 6 3/8 09/01/28 | 149.65 | 50.224B | ||
| A | AGILENT TECHNOLOGIES INC | 21.3 | 36.572B | ||
| IQV | IQVIA HOLDINGS INC | 13.54 | 30.944B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 30.12 | 28.469B | ||
| WAT | WATERS CORP | 22.76 | 19.467B | ||
| ILMN | ILLUMINA INC | 22.48 | 18.232B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 31.36 | 17.522B | ||
| MEDP | MEDPACE HOLDINGS INC | 25.22 | 12.565B |
Related stock screener links
View all stocks in the Life Sciences Tools & Services Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About FTRE
Company Profile
Fortrea Holdings, Inc. engages in the provision of clinical development and commercialization services. The company is headquartered in Durham, North Carolina and currently employs 14,500 full-time employees. The company went IPO on 2023-06-16. The firm is engaged in providing biopharmaceutical product and medical device development services to pharmaceutical, biotechnology and medical device customers. The firm offers customers flexible delivery models that include full service, functional service provider, and hybrid service structures. The company provides phase I-IV clinical trial management, clinical pharmacology and consulting services. The firm manages its business through a single segment, Clinical Services, that provides services across the clinical pharmacology and clinical development spectrum. The firm has access to all key markets worldwide through a footprint of primary office locations in five countries (the United States, the United Kingdom, China, India and Singapore) with field operations in other jurisdictions worldwide.
Company Info
FORTREA HOLDINGS INC
8 Moore Drive
Durham NORTH CAROLINA US
Employees: 14500
Phone: 13026365400
FORTREA HOLDINGS INC / FTRE FAQ
What does FORTREA HOLDINGS INC do?
Fortrea Holdings, Inc. engages in the provision of clinical development and commercialization services. The company is headquartered in Durham, North Carolina and currently employs 14,500 full-time employees. The company went IPO on 2023-06-16. The firm is engaged in providing biopharmaceutical product and medical device development services to pharmaceutical, biotechnology and medical device customers. The firm offers customers flexible delivery models that include full service, functional service provider, and hybrid service structures. The company provides phase I-IV clinical trial management, clinical pharmacology and consulting services. The firm manages its business through a single segment, Clinical Services, that provides services across the clinical pharmacology and clinical development spectrum. The firm has access to all key markets worldwide through a footprint of primary office locations in five countries (the United States, the United Kingdom, China, India and Singapore) with field operations in other jurisdictions worldwide.
What is the current price of FTRE stock?
The current stock price of FTRE is 11.59 USD. The price decreased by -15.22% in the last trading session.
What is the dividend status of FORTREA HOLDINGS INC?
FTRE does not pay a dividend.
How is the ChartMill rating for FORTREA HOLDINGS INC?
FTRE has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the expected growth for FTRE stock?
The Revenue of FORTREA HOLDINGS INC (FTRE) is expected to grow by 0.91% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the market capitalization of FTRE stock?
FORTREA HOLDINGS INC (FTRE) has a market capitalization of 1.07B USD. This makes FTRE a Small Cap stock.
Can you provide the short interest for FTRE stock?
The outstanding short interest for FORTREA HOLDINGS INC (FTRE) is 9.61% of its float.